The binding of the anticoagulant drug phenprocoumon to bovine and human a 1 -acid glycoprotein (AGP) was studied using a fluorescence titration technique. Phenprocoumon was found to have one moderate strength binding site on bovine AGP with n Å (0.78 { 0.04) and a Scatchard association constant, K Å
Enantioselective binding of propranolol, disopyramide, and verapamil to human α1-acid glycoprotein
✍ Scribed by Kazuhiko Hanada; Toshikuni Ohta; Masahiko Hirai; Miki Arai; Hiroyasu Ogata
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 201 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
✦ Synopsis
We investigated the binding of propranolol (PL), disopyramide (DP), and verapamil (VP) enantiomers by human alpha(1)-acid glycoprotein (AGP; also called orosomucoid) and the relationships between the extent of drug binding and lipophilicity, desialylation, and genetic variants of AGP. Desialylation had little effect on the affinity of AGP for the drugs tested. The percentage binding correlated significantly with the partition coefficients for the drugs tested. Each enantiomer was competitively displaced from AGP by another enantiomer of the same drug, suggesting that they bind to the same site. However, the enantiomers bound to AGP with stereospecific affinities; the (-)-isomers of DP and VP had higher Kd values (4.27 and 4.97 microM, respectively) than the (+)-isomers (1.51 and 2.48 microM, respectively). When enantiomers of the different drugs were used in competitive binding experiments, VP binding was only partially inhibited by DP. This result suggested that drug binding is specific to different variants of AGP (A, F1, S). DP was found to specifically bind to variant A, whereas PL and VP bind to both A and F1/S variants.
📜 SIMILAR VOLUMES
A modification of equilibrium dialysis in which a]-acid glycoprotein and plasma compete directly for disopyrarnide has been used in conjunction with binding curves to measure the extent of the al-acid glycoprotein-disopyramide interaction. At concentrations in the therapeutic range, 80-90% of disopy